about
Ceritinib in ALK-rearranged non-small-cell lung cancer.ALK and NSCLC: Targeted therapy with ALK inhibitorsAbsence of anaplastic lymphoma kinase translocations in signet ring cell carcinomas of the upper gastrointestinal tract.Brentuximab vedotin in hodgkin lymphoma and anaplastic large cell lymphomaIdentification of ALK gene alterations in urothelial carcinoma.PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in TaiwanPrognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.Therapeutically Targetable ALK Mutations in LeukemiaPhase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.Spatial organization of the mouse genome and its role in recurrent chromosomal translocationsALK-immunoreactive neoplasms.ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol-3 kinase/Akt activity with retained but inactivated PTEN--a report from the Children's Oncology Group.Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyAnalysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer.Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.Genetics of anaplastic large cell lymphomaA novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in Prostate Cancer Growth.High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.Targeted molecular therapy in peripheral T-cell lymphomas.Anaplastic lymphoma kinase as a therapeutic target.Genomic biomarkers for patient selection and stratification: the cancer paradigm.Kinase dysfunction and kinase inhibitors.Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.Molecular genetics of peripheral T-cell lymphomas.Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.SUMO pathway components as possible cancer biomarkers.Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.A new look at the ALK gene in cancer: copy number gain and amplification.ALK gene alterations in cancer: biological aspects and therapeutic implications.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.(18)F-FDG PET in Patients with Primary Systemic Anaplastic Large Cell Lymphoma: Differential Features According to Expression of Anaplastic Lymphoma KinaseThe use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.The era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy
P2860
Q27852989-16BC1FF1-B281-4627-B424-4ECAC559EC01Q28393324-4522A9A1-B7A3-4F1E-8189-9717DE371A00Q33557250-5EFEBE1E-7C02-471F-B7F2-055440AE572FQ33885565-17428050-7916-4CD7-B1EF-841156304D8CQ33989002-710FDD1D-4CFF-4AFA-B29A-2F2F054986A2Q34489388-DFD05CD1-F121-4EC3-8F2B-7D4D942A764EQ34947842-17BFC77E-447B-4337-99D4-C48EE777C77DQ35013574-F5D8347D-8FFE-4EEF-BF27-6E9A139E1856Q35676273-A4272DD2-1CCE-4E5B-8CC8-95A4858ED4FFQ35743004-957CE01C-05E4-4B83-BCA0-7E4424BD2BCBQ35874015-BBBAD1E7-4F64-450F-A2B3-8952F6E6FF5CQ36092957-BEFC5709-14C0-48C7-AA54-DAFB2A768791Q36094893-F4262458-3105-4993-958F-09D21BFABDE2Q36145016-31FD2ED6-B34C-4DCD-8F8C-1D646F086C67Q36405628-9CE80928-9544-43B1-995E-2714E1434DAFQ36439353-E79082CA-F5A5-4C78-AC04-F46957ACAEA0Q36450307-DD6E7EB6-045B-41FF-A999-594BCB44FF16Q36519797-828D5363-CCCA-46C5-B1C2-9B9C89EF5426Q36893709-A3A4ED2E-9790-4611-8C84-E06E6080E24EQ37290529-09249579-4957-428E-9612-EFD4196631D2Q37385234-1AC3619E-46C1-43B9-981A-EAD003D1377AQ37937044-A0ABBE69-2D5C-4895-9D60-1092ED871D1AQ38045455-3780C481-9713-4B62-B2F0-B5F2E38C30F5Q38060203-8AF54CBD-67DE-46A0-886F-B770FFEAFF70Q38075152-FBE49C47-4C95-48E8-ACBA-6257FF885B14Q38096472-8D5A4C8C-FD6B-4A17-9866-A4DA8E455366Q38106810-1A7FFBCD-02A0-491A-999D-E1F06E427715Q38183757-23A44EB4-AAA5-4D6B-9026-BA3326959FE2Q38194591-7F35C0A9-0996-4AA8-AB8D-5507F263989DQ38214154-303D4E6B-A7D0-479A-9F4A-E8D0ABF72CB6Q38264440-BAB52358-A9C5-42FB-B29E-A1898C790261Q38515816-CCEC57B9-10FC-442A-AB48-5E5AFFBBA882Q38758254-D4A64CA8-6E67-46E0-8710-36AC1255394AQ38760747-81D92920-10BB-40C1-873E-4ECCB919A533Q38767006-08C0D01D-7EE6-408E-83C3-471F0C5093BFQ39028181-BF2116BE-8A0D-4AAE-AFA1-2E19418A31D5Q39794555-8FA25508-9FFD-4029-947A-8EFAFDF4D5B6Q39974450-2982072C-855D-44C8-B580-5643387B8883Q41116766-9AF67A4C-77E4-4C5E-8DC2-5D8E3A59E89AQ41839642-D666BE97-0914-4EE0-AD31-384B06E777DF
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anaplastic lymphoma kinase in human cancer.
@en
type
label
Anaplastic lymphoma kinase in human cancer.
@en
prefLabel
Anaplastic lymphoma kinase in human cancer.
@en
P2093
P50
P356
P1476
Anaplastic lymphoma kinase in human cancer.
@en
P2093
Antonella Barreca
Elena Lasorsa
European T-Cell Lymphoma Study Group
Francesco Bertoni
Giorgio Inghirami
Ludovica Riera
Maurilio Ponzoni
Pier Paolo Piccaluga
Roberto Piva
P304
P356
10.1530/JME-11-0004
P577
2011-07-04T00:00:00Z